MoonLake Immunotherapeutics (MLTX)
Chart Events
Performance Outlook
| Previous Close | 14.00 |
| Open | 14.00 |
| Bid | 13.00 x 800 |
| Ask | 17.92 x 800 |
| Day's Range | 13.15 - 16.00 |
| 52 Week Range | 4.25 - 16.00 |
| Volume | |
| Avg. Volume | 83,926 |
| Market Cap | 572.971M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MLTX
Related Research
- MoonLake ImmunotherapeuticsDaily – Vickers Top Insider Picks for 12/01/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat2 months agoArgus Research
- GlobeNewswire
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an
- GlobeNewswire
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Phase 2 study represents an important step in psoriatic arthritis clinical development, assessing high threshold outcomes across joint and skin domains of this multi-faceted diseaseGlobal study to assess efficacy and safety of sonelokimab compared to placebo, with adalimumab as an active reference armSonelokimab is an investigational Nanobody® designed to treat inflammato
- GlobeNewswire
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa (HS) has continued to meet recruitment targets with an expected primary endpoint readout in mid-2023Global Psoriatic Arthritis (PsA) trial received FDA clearance and US central IRB approvalQuarter-end position of $83.5 million in cash, cash equivalents and short-term marketable debt securities, providing cash runway into 2H2024 and a
